Three analysts have issued estimates for Amarin Corporation PLC's earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.06). Quantitative Investment Mgmt Ltd Liability Company accumulated 91,600 shares or 0.01% of the stock.
The main U.S. indices ended Friday's session weaker, as United States economic growth cooled to the slowest pace in three years in the first quarter and geopolitical concerns reemerged. UBS Group AG boosted its position in Amarin Corporation PLC by 7.4% in the first quarter. Tower Research Capital Ltd Liability Corp (Trc) holds 2,373 shares.
Amarin Co. plc (NASDAQ:AMRN) last posted its earnings results on Wednesday, August 2nd. The hedge fund held 7.94 million shares of the major pharmaceuticals company at the end of 2016Q4, valued at $24.44 million, up from 6.09 million at the end of the previous reported quarter.
4 number of analysts have estimated the sales of the company for the quarter, analysts estimated mean sale target of 48.03 million while high and low sale targets are estimated at 51.7 million and 44 million respectively. During the same period a year ago, the firm earned ($0.07) EPS. Point72 Asset Management L.P. bought a new position in shares of Amarin Corporation PLC during the first quarter valued at about $960,000. Cetera Advsrs Llc reported 0% in Amarin Corporation plc (ADR) (NASDAQ:AMRN). BidaskClub raised shares of Amarin Corporation PLC from a "buy" rating to a "strong-buy" rating in a research note on Thursday, July 6th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a research report on Monday, June 26th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock.
Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $7.6 on the stock, this valuation is based on 5 number of opinions.
Amarin Corp PLC (NASDAQ:AMRN) institutional sentiment decreased to 1.63 in Q4 2016. The stock exchanged hands 2.63 Million shares versus average trading capacity of 2.42 Million shares. Amarin Co. plc has a one year low of $2.56 and a one year high of $4.47. The stock's 50-day moving average price is $3.87 and its 200-day moving average price is $3.31. The firm's market capitalization is $882.78 million. They now have a Dollars 1.5 price target on the stock. H.C. Wainwright maintained the shares of AMRN in report on Thursday, August 3 with "Buy" rating. Raymond James Financial Services Advisors Inc. now owns 143,650 shares of the biopharmaceutical company's stock valued at $460,000 after buying an additional 2,050 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in Amarin Corporation PLC by 1.4% in the first quarter. Morgan Stanley now owns 1,138,992 shares of the biopharmaceutical company's stock valued at $3,645,000 after buying an additional 620,577 shares in the last quarter. Wells Fargo & Company MN increased its stake in Amarin Corporation PLC by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company's stock worth $105,000 after buying an additional 1,500 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Amarin Corporation PLC by 662.8% in the fourth quarter. California Public Employees Retirement System now owns 533,300 shares of the biopharmaceutical company's stock worth $1,707,000 after buying an additional 62,800 shares during the period. Oracle Investment Management Inc owns 7.94 million shares or 4.05% of their USA portfolio. Corporate insiders own 3.72% of the company's stock. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2017/08/10/bidaskclub-lowers-amarin-corporation-plc-amrn-to-buy-updated.html. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & global copyright & trademark law.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health.